Back

Genetically informed search for potential osteoarthritis drug targets across the proteome

2026-02-11 rheumatology Title + abstract only
View on medRxiv
Show abstract

BackgroundOsteoarthritis (OA) is a leading cause of disability worldwide, yet no licensed therapies can prevent or slow its progression. We aimed to identify potential targets for disease-modifying OA drugs (DMOADs) by integrating genetic and differential protein expression (DPE) evidence. MethodsWe evaluated genetically predicted perturbations of plasma protein levels using cis-protein quantitative trait loci (cis-pQTLs) across three large European cohorts (UK Biobank Pharma Proteomics Project...

Predicted journal destinations

1
Arthritis & Rheumatology
21 training papers
Top 0.1% 24.7%
2
Nature Communications
483 training papers
Top 4% 16.2%
3
Rheumatology
21 training papers
Top 0.4% 13.1%
4
Annals of the Rheumatic Diseases
23 training papers
Top 0.5% 8.6%
5
Scientific Reports
701 training papers
Top 51% 5.6%
6
JCI Insight
63 training papers
Top 1% 4.3%
7
The American Journal of Human Genetics
77 training papers
Top 6% 2.4%
8
PLOS ONE
1737 training papers
Top 91% 2.2%
9
Frontiers in Immunology
140 training papers
Top 7% 1.7%
10
eLife
262 training papers
Top 27% 1.7%
11
npj Digital Medicine
85 training papers
Top 11% 1.7%
12
eBioMedicine
82 training papers
Top 8% 1.1%
13
International Journal of Epidemiology
65 training papers
Top 9% 1.1%
14
Human Molecular Genetics
28 training papers
Top 6% 1.1%
15
Thorax
29 training papers
Top 2% 0.8%
16
Cell Reports Medicine
49 training papers
Top 6% 0.8%
17
BMJ Open
553 training papers
Top 70% 0.6%
18
Nature Genetics
72 training papers
Top 11% 0.6%
19
International Journal of Molecular Sciences
39 training papers
Top 9% 0.5%
20
BMC Medicine
155 training papers
Top 42% 0.5%
21
iScience
74 training papers
Top 16% 0.5%
22
Proceedings of the National Academy of Sciences
100 training papers
Top 25% 0.5%
23
Human Genetics and Genomics Advances
39 training papers
Top 7% 0.5%
24
Genome Medicine
56 training papers
Top 9% 0.5%